Forteo Dosage/Direction for Use

Posology: The recommended dose of FORTEO is 20 micrograms administered once daily.
The maximum total duration of treatment with FORTEO should be 24 months (see Precautions). The 24-month course of Forteo should not be repeated over a patient's lifetime.
Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.
Following cessation of FORTEO therapy, patients may be continued on other osteoporosis therapies.
Special populations: Patients with renal impairment: FORTEO must not be used in patients with severe renal impairment (see Contraindications). In patients with moderate renal impairment, FORTEO should be used with caution. No special caution is required for patients with mild renal impairment.
Patients with hepatic impairment: No data are available in patients with impaired hepatic function (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Therefore, FORTEO should be used with caution.
Paediatric population and young adults with open epiphyses: The safety and efficacy of FORTEO in children and adolescents less than 18 years has not been established. FORTEO should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses.
Elderly patients: Dosage adjustment based on age is not required (see Pharmacology: Pharmacokinetics under Actions).
Method of administration: FORTEO should be administered once daily by subcutaneous injection in the thigh or abdomen.
Patients must be trained to use the proper injection techniques (see Special precautions for disposal under Cautions for Usage). A user manual is also available to instruct patients on the correct use of the pen.